Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

952 Followers
See the Price Targets and Ratings of:

JAZZ Analyst Ratings

Strong Buy
10Ratings
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Jazz
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JAZZ Stock 12 Months Forecast

Average Price Target

$195.40
▲(25.22% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $195.40 with a high forecast of $210.00 and a low forecast of $180.00. The average price target represents a 25.22% change from the last price of $156.05.
Highest Price Target$210.00Average Price Target$195.40Lowest Price Target$180.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Morgan Stanley
$187.00
Hold
19.83%
Upside
Reiterated
Morgan Stanley Sticks to Their Hold Rating for Jazz Pharmaceuticals (JAZZ)
UBS
$191.00
Buy
22.40%
Upside
Reiterated
Jazz Pharmaceuticals (JAZZ) PT Lowered to $191 at UBSUBS analyst Ashwani Verma lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $191.00 (from $194.00) while maintaining a Buy rating.
Stifel Nicolaus
$210.00
Buy
34.57%
Upside
Reiterated
Stifel reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ) as Nabiximols Trials DisappointStifel analyst Annabel Samimy reiterated a Buy rating and $210.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) as Nabiximols trials disappoint.
Barclays
$240.00
Buy
53.80%
Upside
Reiterated
Barclays Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Cowen & Co.
$225.00
Buy
44.18%
Upside
Reiterated
Jazz Pharmaceuticals price target raised to $225 from $200 at CowenJazz Pharmaceuticals price target raised to $225 from $200 at Cowen
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

JAZZ Financial Forecast

JAZZ Earnings Forecast
Next quarter’s earnings estimate for JAZZ is $4.42 with a range of $3.85 to $4.76. The previous quarter’s EPS was $5.17. JAZZ beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.38% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.
Next quarter’s earnings estimate for JAZZ is $4.42 with a range of $3.85 to $4.76. The previous quarter’s EPS was $5.17. JAZZ beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.38% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.
JAZZ Sales Forecast
Next quarter’s sales forecast for JAZZ is $970.54M with a range of $942.40M to $989.52M. The previous quarter’s sales results were $940.65M. JAZZ beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.90% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.
Next quarter’s sales forecast for JAZZ is $970.54M with a range of $942.40M to $989.52M. The previous quarter’s sales results were $940.65M. JAZZ beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.90% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.
JAZZ Analyst Recommendation Trends
In the current month, JAZZ has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The JAZZ average analyst price target in the past 3 months is $195.40
In the current month, JAZZ has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The JAZZ average analyst price target in the past 3 months is $195.40

JAZZ Stock Forecast FAQ

What is JAZZ’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is $195.40.
    What is JAZZ’s upside potential, based on the analysts’ average price target?
    Jazz Pharmaceuticals has 25.22% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JAZZ a Buy, Sell or Hold?
          Jazz Pharmaceuticals has a conensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Jazz Pharmaceuticals’s price target?
            The average price target for Jazz Pharmaceuticals is $195.40. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $210.00 ,the lowest forecast is $180.00. The average price target represents 25.22% Increase from the current price of $156.05.
              What do analysts say about Jazz Pharmaceuticals?
              Jazz Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis